Smart Pills Market to Witness Significant Expansion, Reaching US$3.5 Billion by 2034

Overview

The Global Smart Pills Market Size is expected to be worth around US$ 3.5 Billion by 2034, from US$ 1.2 Billion in 2024, growing at a CAGR of 11.2% during the forecast period from 2025 to 2034.

The Global Smart Pills Market is gaining attention as advances in ingestible sensors, wireless communication, miniaturized electronics, and digital health technologies create new approaches to monitoring and managing health conditions. Smart pills can be designed to collect physiological information inside the gastrointestinal tract, confirm medication ingestion, or support targeted drug-delivery applications.

The U.S. Food and Drug Administration (FDA) recognizes ingestible event markers as medical devices designed to provide confirmation of an event associated with an ingestible component. FDA records describe systems combining a swallowable microsensor with a wearable patch and software for transmitting ingestion-related information.

Research supported by the National Institutes of Health (NIH) has further highlighted the potential of swallowable technologies for gastrointestinal monitoring, disease investigation, microbiome research, and controlled drug delivery. NIH-supported research demonstrated an ingestible sensor that operated in animal testing for up to 29 days, recording measurements every 10 minutes.

As healthcare increasingly emphasizes minimally invasive diagnostics, medication adherence, personalized treatment, and continuous physiological monitoring, smart pills are emerging as an important area of innovation. Ongoing research is expected to focus on sensor miniaturization, safety, reliable wireless data transmission, targeted therapies, and integration with digital healthcare platforms.

Key Takeaways

• The global smart pills market was valued at USD 1.2 billion in 2024 and is projected to reach USD 3.5 billion by 2034, registering a CAGR of 11.2% during the forecast period.
• In 2024, the celiac disease segment dominated the global smart pills market, accounting for 26.7% of the total revenue share.
• The small intestine segment held the leading position in the global market in 2024, capturing 28.6% of the total revenue share.
• The capsule endoscopy segment emerged as the leading segment in 2024, representing 53.3% of the global smart pills market revenue.
• The hospitals segment dominated the market in 2024, accounting for 66.7% of the total revenue share.
• North America maintained its leadership in the global smart pills market in 2024, capturing more than 37.8% of the total market revenue.

Statistical Information

• The U.S. FDA cleared the NaviCam Small Bowel Capsule Endoscopy System on January 5, 2024, under 510(k) number K233229, supporting the continued regulatory adoption of wireless capsule technologies.
• In 2026, the FDA cleared Deep Capsule US, an AI-based gastrointestinal capsule endoscopy analysis software, under 510(k) K250655, with the decision issued on March 12, 2026.
• The FDA cleared PillCam Genius SB System in May 2024 under 510(k) K240276, with testing covering pH resistance, mechanical integrity, battery reliability, communication performance, usability, and electromagnetic compatibility.
• The NIDDK estimates that about 2 million people in the United States have celiac disease, while many individuals remain undiagnosed, supporting continued demand for gastrointestinal diagnostic technologies.
• The National Cancer Institute estimated 13,920 new cases and 2,060 deaths from small-intestine cancer in the United States in 2025, highlighting the clinical need for technologies capable of examining difficult-to-access gastrointestinal areas.
• A patient study involving 40 people found that 77.5% would prefer colon capsule endoscopy for a future bowel investigation. Patients also rated capsule endoscopy’s mean comfort at 9.2 versus 6.7 for colonoscopy.
• The FDA cleared CapsoCam Plus (SV-3) Capsule Endoscopy System in December 2024, under 510(k) K242643, demonstrating continued commercial development of capsule-based gastrointestinal imaging in the U.S.
• The FDA’s magnetically maneuvered capsule classification identifies Class II systems designed to visualize the stomach and duodenum, with an external magnetic controller directing the capsule’s location and viewing direction.

Market Segmentation Analysis

Disease Indication Analysis

Based on disease indication, the market includes celiac disease, occult GI bleeding, Crohn’s disease, small bowel tumors, inherited polyposis syndromes, neurological disorders, and others. The celiac disease segment dominated in 2024, accounting for 26.7% of the global smart pills market. Growing demand for non-invasive gastrointestinal diagnostics is supporting adoption, particularly as conventional endoscopy and biopsy procedures can be invasive.

Smart pills can facilitate gastrointestinal monitoring and provide clinicians with useful information about disease progression and treatment response. Their potential to support continuous monitoring also aligns with the increasing focus on personalized healthcare. Technological advancements in ingestible sensors and diagnostic systems are expected to further strengthen the role of smart pills in managing celiac disease.

Target Area Analysis

Based on target area, the market is segmented into the small intestine, esophagus, large intestine, and stomach. The small intestine segment led the market in 2024 with a 28.6% revenue share. The segment benefits from increasing demand for minimally invasive approaches to investigating gastrointestinal disorders affecting difficult-to-reach areas.

Smart pills can capture information related to gastrointestinal conditions while traveling through the digestive tract, supporting evaluation of disorders such as Crohn’s disease and celiac disease.

Compared with conventional invasive procedures, ingestible technologies can improve patient convenience and enable outpatient diagnostic approaches. Continued advances in sensor technology, imaging, wireless connectivity, and data analysis are expected to expand applications focused on small-intestinal health.

Application Analysis

By application, the market is divided into capsule endoscopy, drug delivery, and vital sign monitoring. Capsule endoscopy dominated the global smart pills market in 2024, capturing 53.3% of revenue. Its leading position is supported by the ability to examine the gastrointestinal tract using a swallowable camera-equipped capsule. The technology provides images from areas that can be challenging to evaluate using conventional endoscopic approaches, particularly within the small intestine.

Capsule endoscopy can support the investigation of conditions including Crohn’s disease, celiac disease, and unexplained gastrointestinal bleeding. Its minimally invasive nature, reduced patient discomfort, and potential for outpatient use have encouraged adoption. Improvements in imaging, data processing, and capsule technology are expected to sustain segment growth.

End-User Analysis

Based on end user, the market is categorized into hospitals, diagnostic centers, and others. Hospitals held the dominant position in 2024, accounting for 66.7% of the global smart pills market revenue. Hospitals increasingly utilize smart pill technologies to support minimally invasive gastrointestinal diagnosis and patient monitoring.

Capsule-based systems can assist healthcare professionals in evaluating conditions such as Crohn’s disease, celiac disease, gastrointestinal bleeding, and digestive-system disorders. The ability to obtain diagnostic information without conventional invasive procedures can improve patient convenience while supporting efficient clinical workflows.

Hospitals also benefit from technological advances that enhance image quality, data interpretation, and digital integration. Growing adoption of advanced diagnostic technologies and the increasing emphasis on patient-centered care are expected to support continued demand in hospital settings.

Regional Analysis

North America maintains a leading position in the global smart pills market, supported by advanced healthcare infrastructure, established gastroenterology services, and the adoption of wireless diagnostic technologies. The United States has also established a regulatory pathway for capsule-based gastrointestinal technologies. The U.S. Food and Drug Administration (FDA) has cleared multiple wireless capsule endoscopy systems, including the NaviCam Small Bowel Capsule Endoscopy System in 2024 and the PillCam SB 3 system in 2023.

Clinical demand further supports regional adoption. The U.S. National Institute of Diabetes and Digestive and Kidney Diseases reports that more than 20 million GI endoscopies are performed annually in the United States, highlighting the substantial need for gastrointestinal diagnostic technologies.

The American Society for Gastrointestinal Endoscopy recognizes video capsule endoscopy for evaluating obscure gastrointestinal bleeding, Crohn’s disease, small-bowel tumors, and selected celiac disease cases. These applications, combined with ongoing technological development, are expected to support North America’s continued market leadership.

Business Opportunities

The smart pills market presents significant business opportunities across gastrointestinal diagnostics, targeted drug delivery, physiological monitoring, and digital healthcare integration. Capsule endoscopy remains a major commercial opportunity because professional guidelines recognize its use for small-bowel bleeding, Crohn’s disease, inherited polyposis syndromes, suspected tumors, and selected celiac disease cases.

A key opportunity lies in developing next-generation ingestible sensors capable of measuring pH, temperature, pressure, gases, biomarkers, and other gastrointestinal parameters. Research indicates that smart capsules can collect physiological information throughout the gastrointestinal tract, creating opportunities for precision diagnostics and personalized monitoring.

Drug-delivery systems represent another promising area. NIH-supported research has demonstrated the potential of swallowable devices for long-term monitoring and controlled drug release, while recent research has explored real-time monitoring of oral drug-release processes. Additional opportunities include AI-powered image analysis, cloud-connected diagnostic platforms, remote monitoring services, and interoperable software that helps clinicians process and interpret data generated by ingestible devices.

Emerging Trends

• Chemical and Biomarker Sensing: Smart pills are moving beyond imaging toward chemical sensing inside the gastrointestinal tract. Newer capsule concepts can detect local chemical conditions and biomarkers, potentially giving clinicians more detailed information about gut health and supporting earlier, more precise diagnosis.
• Robotic Capsule Development: Research is shifting toward robotic capsules capable of performing active functions rather than simply traveling through the digestive system. Development includes mechanisms for localization, retention, movement, sampling, and controlled intervention inside specific gastrointestinal regions.
• Microbiome-Focused Technologies: Smart-pill development is increasingly targeting regional microbiome analysis. NIH-supported research is evaluating ingestible capsules that can collect gastrointestinal samples and study microbiota and metabolite changes at different locations along the digestive tract.
• Miniaturized Multi-Sensor Platforms: Advances in microelectronics are enabling smaller capsules that combine multiple sensing functions. Research is exploring electrochemical, optical, electromagnetic, and acoustic technologies, allowing one ingestible device to investigate several gastrointestinal parameters.
• Real-Time Drug-Release Monitoring: A new research direction is using smart capsules to observe how oral medicines dissolve and release inside the gastrointestinal tract. A 2026 Purdue University study demonstrated a capsule designed to monitor drug-release processes in real time.

Use Cases

• Regional Gut Microbiome Sampling: Ingestible sampling capsules can collect material from specific gastrointestinal regions for microbiome and metabolome analysis. NIH-funded CapScan research is evaluating regional differences in patients with small-intestinal bacterial overgrowth before and after antibiotic treatment.
• Precision Nutrition Research: Smart pills can help researchers examine how dietary components interact with the gut microbiome in specific gastrointestinal locations. NIH has specifically identified swallowable devices as tools for studying host-diet interactions and microbiome ecology.
• Gastrointestinal Drug Development: Ingestible sensors can measure transit time, pH, temperature, and pressure, helping pharmaceutical researchers understand the environment experienced by oral medicines and improve drug formulation and delivery strategies.
• Localized Therapeutic Delivery: Smart capsules are being investigated for delivering therapeutic compounds directly to selected gastrointestinal locations. This approach could concentrate treatment near diseased tissue while potentially reducing exposure to healthy areas.
• Stomach-Condition Monitoring: Swallowable devices are being investigated for monitoring stomach conditions and potentially providing prolonged measurements. NIH-supported research has explored expandable ingestible sensors designed to remain in the stomach and potentially support controlled drug delivery.

Recent Developments

• In July 2026, AnX Robotica launched NaviCONNECT™, a cloud-based platform for capsule endoscopy, providing secure remote access to capsule studies and reports while supporting workflow management, software updates, enterprise connectivity, and a foundation for future AI capabilities.
• In May 2026, IntroMedic Co., Ltd. received U.S. FDA 510(k) clearance for its MiroCam® Capsule Endoscope System, with the FDA recording a substantially equivalent decision on May 8, 2026, strengthening IntroMedic’s U.S. capsule-endoscopy presence.
• In December 2025, Check-Cap entered an agreement giving a selling shareholder the right to purchase up to US$ 30 million of its ordinary shares over three years, subject to conditions; Check-Cap agreed to issue commitment-fee shares equal to 1.5% of the total commitment. This was corporate financing rather than funding specifically for smart-pill development.
• In July 2025, CapsoVision closed its initial public offering of 5.5 million shares at US$ 5.00 per share, generating US$ 27.5 million in gross proceeds before offering expenses. The company develops imaging and AI technologies used in its capsule-endoscopy solutions.

Conclusion
The global smart pills market is advancing as healthcare providers increasingly seek minimally invasive, precise, and technology-driven diagnostic and monitoring solutions. Capsule endoscopy remains a major application, while emerging developments in ingestible sensors, AI-assisted analysis, microbiome sampling, robotic capsules, and targeted drug delivery are broadening the market’s potential.

Regulatory clearances and product launches in the United States further demonstrate growing technological maturity and clinical adoption. Increasing gastrointestinal disease burden, demand for patient-friendly diagnostics, and investment in digital healthcare are creating new commercial opportunities. Going forward, improvements in sensor miniaturization, connectivity, data interpretation, safety, and personalized treatment are expected to shape smart-pill innovation and adoption.